NASDAQ:GDTC

CytoMed Therapeutics H1 2026 Earnings Results & Report

CytoMed Therapeutics logo
$0.83 +0.05 (+6.00%)
Closing price 03:59 PM Eastern
Extended Trading
$0.82 -0.01 (-1.33%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CytoMed Therapeutics reported H1 2026 earnings on September 30, 2026. The company reported EPS of $0.05, while revenue was $60.77 thousand.

Earnings Announcement Details

Quarter
H1 2026
Time
Before Market Opens

CytoMed Therapeutics EPS Results

Actual EPS
$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CytoMed Therapeutics Revenue Results

Actual Revenue
$60.77 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CytoMed Therapeutics H1 2026 Earnings FAQ

CytoMed Therapeutics (NASDAQ:GDTC) reported earnings of $0.05 per share for H1 2026. The report was announced on Wednesday, September 30, 2026.

CytoMed Therapeutics reported revenue of $60.77 thousand for H1 2026.

CytoMed Therapeutics Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More CytoMed Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoMed Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoMed Therapeutics and other key companies, straight to your email.

About CytoMed Therapeutics

CytoMed Therapeutics (NASDAQ:GDTC) Ltd. is a Singapore-based biotechnology company developing cell-based immunotherapies for cancer. Its research focuses on gamma delta T cells, a type of immune cell, and induced pluripotent stem cell-derived cells for potential use in cancer treatment.

The company is developing allogeneic therapies, which are made using cells from donors rather than each patient’s own cells. Its programs are in development, and CytoMed does not have a marketed cancer treatment.

Founded in 2018, CytoMed conducts research and development in Singapore and has pursued clinical development activities in the region. Its work is focused on advancing potential therapies through development and testing rather than serving patients through a commercial product portfolio.

View CytoMed Therapeutics Profile